Clinical trials: Heart Infarction
Myocardial Infarction
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2 study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily doses) versus ramipril administered orally BID…
- Trial name
- QUORUM (NCT03715998)
- Testing
- Ramipril, Firibastat
- Where
- 7 sites in France, Germany and 5 more
- Volunteers
- 295 people
- Sponsor
- Quantum Genomics SA
Coronary Artery Bypass Graft Redo, Heart Valve Diseases
SONOlysis in Risk REduction of Symptomatic and Silent Brain infarCtions dUring Cardiac surgEry
The aim of the project is to demonstrate a fibrinolytic effect of sonothrombolysis (continual transcranial Doppler monitoring) using 2 MHz diagnostic probe on the reduction of risk of brain infarctions due to the activation of…
- Trial name
- SONORESCUE (NCT01591018)
- Testing
- sonolysis, cardiac surgery
- Where
- Czechia
- Volunteers
- 120 people
- Sponsor
- University Hospital Ostrava
Cardiovascular Disease
Heart Attack Prevention Programme for You (HAPPY) London
Diseases of the heart and blood vessels, such as heart attacks and strokes, are very common and can lead to severe disability or death.
- Trial name
- HAPPYLondon (NCT01911910)
- Testing
- Electronic coaching plus standard care
- Where
- United Kingdom
- Volunteers
- 402 people
- Sponsor
- Queen Mary University of London
Myocardial Reperfusion Injury
Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Percutaneous coronary intervention (PCI) for acute coronary syndromes frequently fails to restore myocardial perfusion despite establishing epicardial vessel patency.
- Trial name
- BQ-123 (NCT00586820)
- Testing
- BQ-123
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Cardiogenic Shock, Acute Myocardial Infarction
National Cardiogenic Shock Initiative
This study evaluates the use of early mechanical circulatory support in patients presenting with acute myocardial infarction and cardiogenic shock.
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCSI (NCT03677180)
- Where
- 75 sites in United States
- Volunteers
- 406 people
- Sponsor
- Henry Ford Health System
ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease
Metformin to Reduce Heart Failure After Myocardial Infarction
The investigators will evaluate the effect of metformin therapy during 4 months in non-diabetic patients following ST-elevation myocardial infarction on left ventricular ejection fraction as measured with cardiac magnetic…
- Conditions
- ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease, Heart Failure, Diabetes
- Trial name
- GIPS-III (NCT01217307)
- Testing
- Metformin
- Where
- Netherlands
- Volunteers
- 380 people
- Sponsor
- University Medical Center Groningen
Myocardial Infarction, Myocardial Infarction, Acute
BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction
The BIO|GUARD-MI study investigates whether continuous arrhythmia monitoring and the consequent treatment after detected arrhythmias in patients after myocardial infarction with preserved cardiac function, but other risk factors…
- Conditions
- Myocardial Infarction, Myocardial Infarction, Acute, Myocardial Infarction Old
- Trial name
- BIO-GUARD-MI (NCT02341534)
- Testing
- BioMonitor
- Where
- 59 sites in United States, Australia and 12 more
- Volunteers
- 802 people
- Sponsor
- Biotronik SE & Co. KG
Acute ST Segment Elevation Myocardial Infarction
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial…
- Trial name
- NCT04463251
- Testing
- RPH-104 80 mg
- Where
- 11 sites in United States, Russia
- Volunteers
- 102 people
- Sponsor
- R-Pharm Overseas, Inc.
Coronary Arteriosclerosis, Myocardial Infarction
Culturally-Tailored Approach to Improve Medication Use in Patients With Heart Attacks
Our research aims to improve the use of medicines known to prevent recurrent heart attacks. In particular, we know that statin treatment is useful after heart attacks, but many patients do not use it.
- Trial name
- NCT00426231
- Testing
- Navigation by a health worker, Information control
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Johns Hopkins University
Myocardial Infarction
Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure Improvement
One emerging concept is that some form of injury or inflammation is a prerequisite for the success of circulating-cell participation in differentiated tissue structure and function.
- Trial name
- NCT00154466
- Testing
- cardiac rehabilitation
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- National Taiwan University Hospital
Angina, Unstable, Cardiovascular Diseases
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established…
- Conditions
- Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease
- Trial name
- IMMEDIATE (NCT00091507)
- Testing
- GIK
- Where
- 13 sites in United States
- Volunteers
- 911 people
- Sponsor
- Tufts Medical Center
Stem Cell Transplantation, Ventricular Dysfunction, Left
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional…
- Trial name
- TAC-HFT (NCT00768066)
- Testing
- Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Miami
Myocardial Infarction
Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)
Patients with partially blocked blood vessel(s) in their heart may need a medical procedure called "Percutaneous Coronary Intervention (PCI)" to open the narrowed blood vessel(s).
- Trial name
- NCT02939976
- Testing
- Single Vessel Disease, Multi-vessel Disease, Culprit Vessel Only, Multi-vessel Disease, Complete Revascularization
- Where
- United States
- Volunteers
- 427 people
- Sponsor
- David Kong, M.D.
Tachycardia, Diabetes Mellitus
Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator
The MADIT S-ICD trial was designed to evaluate if subjects with a prior myocardial infarction, diabetes mellitus and a relatively preserved ejection fraction of 36-50% will have a survival benefit from receiving a subcutaneous…
- Conditions
- Tachycardia, Diabetes Mellitus, Cardiovascular Disease
- Trial name
- MADIT S-ICD (NCT02787785)
- Testing
- Subcutaneous Implantable Cardioverter Defibrillator
- Where
- 49 sites in United States, Germany and 5 more
- Volunteers
- 40 people
- Sponsor
- Boston Scientific Corporation
Cardiogenic Shock
Early Insertion of Axillary Impella® With VA ECMO
Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is used as a rescue strategy for patients in acute hemodynamic deterioration such as cardiogenic shock and cardiopulmonary arrest with severe pulmonary congestion.
- Trial name
- NCT04084015
- Testing
- Axillary Impella®
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Acute Myocardial Infarction
Sodium Nitrite in Acute Myocardial Infarction
The purpose of this study is to determine whether the intravenous infusion of sodium nitrite safely prevents ischemia-reperfusion injury in subjects with acute myocardial infarction resulting in improved left ventricular function.
- Trial name
- NCT00924118
- Testing
- Sodium Nitrite
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Acute Anterior Myocardial Infarction
The INFUSE - Anterior Myocardial Infarction (AMI) Study
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites.
- Trial name
- NCT00976521
- Testing
- Abciximab local infusion, No local infusion, Thrombus aspiration
- Where
- 38 sites in United States, Austria and 4 more
- Volunteers
- 452 people
- Sponsor
- Atrium Medical Corporation
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Diabetes, Myocardial Infarction
Trial to Assess Chelation Therapy 2
Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in…
- Trial name
- TACT2 (NCT02733185)
- Testing
- disodium EDTA, Oral Multi Vitamins/Minerals (OMVM)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Cardiovascular Diseases, Heart Diseases
Electrophysiological Effects of Late PCI After MI
The purpose of this study is to determine if opening blocked arteries with heart balloons and stents prevents heart rhythm problems in individuals 3 to 28 days after a heart attack.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Coronary Disease
- Trial name
- NCT00119847
- Testing
- PCI, Optimal Medical Therapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Maryland, Baltimore